Target Name: NR1D2
NCBI ID: G9975
Review Report on NR1D2 Target / Biomarker Content of Review Report on NR1D2 Target / Biomarker
NR1D2
Other Name(s): Nuclear receptor subfamily 1 group D member 2, transcript variant 1 | NR1D2_HUMAN | NR1D2 variant 1 | nuclear receptor Rev-ErbA beta variant 2 | Rev-erb alpha-related receptor | nuclear receptor subfamily 1 group D member 2 | RVR | HZF2 | Rev-erb-beta | REVERBbeta | orphan nuclear hormone receptor BD73 | BD73 | Orphan nuclear receptor NR1D2 | Nuclear receptor subfamily 1 group D member 2 (isoform 1) | nuclear receptor Rev-ErbA beta variant 1 | Orphan nuclear hormone receptor BD73 | V-erbA-related protein 1-related | rev-erb-beta | REVERBB | EAR-1R | Nuclear receptor subfamily 1 group D member 2 | EAR-1r | rev-erb alpha-related receptor | Hs.37288 | rev-erba-alpha-related receptor

NR1D2: A Nuclear Receptor Subfamily 1 Group D Member 2 Molecule as a Potential Drug Target and Biomarker

Abstract:

Nuclear receptor subfamily 1 group D member 2 (NR1D2) is a G protein-coupled receptor (GPCR) that plays a crucial role in various physiological processes in the body. The humanNR1D2 gene has four exons, and its corresponding transcript variant 1 is a widely used gene in research and drug development. This gene has been associated with various diseases, including cancer, obesity, and neurodegenerative disorders. In this article, we will discuss the potential drug target and biomarker properties of NR1D2.

Introduction:

Nuclear receptor subfamily 1 group D member 2 (NR1D2) is a GPCR that is expressed in various tissues and cell types in the body. It is a member of the subfamily 1 group D, which includes several related genes, including the neurotransmitter receptor subfamily 1 group D member 1 (NR1D1), neurotransmitter receptor subfamily 1 group E member 1 (NR1DE), and neurotransmitter receptor subfamily 1 group F member 1 (NR1DF).

NR1D2 is a 149 amino acid protein that has four exons. It has a split signal peptide and a long N-terminus that contains a putative G protein-coupled receptor transmembrane domain (GTPase domain), a catalytic domain, and a carboxylic acid (Ca2+) binding site. The catalytic domain is responsible for the interaction with GTP and the G protein-coupled receptor transmembrane domain, which is responsible for the catalytic activity of the receptor.

NR1D2 is involved in various physiological processes, including sensory perception, neurotransmission, and cellular signaling. It has been shown to be involved in the regulation of pain, anxiety, and depression. It is also involved in the regulation of body weight and metabolism, which is related to the development of various diseases, including cancer and obesity.

Drugs that target NR1D2 have been shown to have therapeutic potential in various diseases. For example, compounds that can inhibit the NR1D2 receptor have been shown to be effective in treating anxiety and depression. Additionally, compounds that can activate the NR1D2 receptor have been shown to be effective in treating pain.

NR1D2 has also been shown to be a potential biomarker for various diseases, including cancer. For example, studies have shown that high levels of NR1D2 expression are associated with poor prognosis in patients with pancreatic cancer. Additionally,NR1D2 has been shown to be involved in the regulation of cancer cell growth and metastasis.

Conclusion:

In conclusion, NR1D2 is a GPCR that plays a crucial role in various physiological processes in the body. It is a potential drug target and biomarker for various diseases, including cancer and obesity. Further research is needed to fully understand the role of NR1D2 in diseases and to develop effective treatments.

Protein Name: Nuclear Receptor Subfamily 1 Group D Member 2

Functions: Transcriptional repressor which coordinates circadian rhythm and metabolic pathways in a heme-dependent manner. Integral component of the complex transcription machinery that governs circadian rhythmicity and forms a critical negative limb of the circadian clock by directly repressing the expression of core clock components BMAL1 and CLOCK. Also regulates genes involved in metabolic functions, including lipid metabolism and the inflammatory response. Acts as a receptor for heme which stimulates its interaction with the NCOR1/HDAC3 corepressor complex, enhancing transcriptional repression. Recognizes two classes of DNA response elements within the promoter of its target genes and can bind to DNA as either monomers or homodimers, depending on the nature of the response element. Binds as a monomer to a response element composed of the consensus half-site motif 5'-[A/G]GGTCA-3' preceded by an A/T-rich 5' sequence (RevRE), or as a homodimer to a direct repeat of the core motif spaced by two nuclegotides (RevDR-2). Acts as a potent competitive repressor of ROR alpha (RORA) function and also negatively regulates the expression of NR1D1. Regulates lipid and energy homeostasis in the skeletal muscle via repression of genes involved in lipid metabolism and myogenesis including: CD36, FABP3, FABP4, UCP3, SCD1 and MSTN. Regulates hepatic lipid metabolism via the repression of APOC3. Represses gene expression at a distance in macrophages by inhibiting the transcription of enhancer-derived RNAs (eRNAs). In addition to its activity as a repressor, can also act as a transcriptional activator. Acts as a transcriptional activator of the sterol regulatory element-binding protein 1 (SREBF1) and the inflammatory mediator interleukin-6 (IL6) in the skeletal muscle (By similarity). Plays a role in the regulation of circadian sleep/wake cycle; essential for maintaining wakefulness during the dark phase or active period (By similarity). Key regulator of skeletal muscle mitochondrial function; negatively regulates the skeletal muscle expression of core clock genes and genes involved in mitochondrial biogenesis, fatty acid beta-oxidation and lipid metabolism (By similarity). May play a role in the circadian control of neutrophilic inflammation in the lung (By similarity)

The "NR1D2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NR1D2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3 | NRIP3-DT | NRIR | NRK | NRL | NRM | NRN1 | NRN1L | NRON | NRP1 | NRP2 | NRROS | NRSN1 | NRSN2 | NRSN2-AS1 | NRTN | NRXN1 | NRXN2 | NRXN2-AS1 | NRXN3 | NSA2 | NSA2P2 | NSD1 | NSD2 | NSD3 | NSDHL | NSF | NSFL1C | NSFP1 | NSG1 | NSG2 | NSL complex | NSL1 | NSMAF | NSMCE1 | NSMCE1-DT | NSMCE2 | NSMCE3 | NSMCE4A | NSMF | NSRP1 | NSUN2 | NSUN3 | NSUN4 | NSUN5 | NSUN5P1 | NSUN5P2 | NSUN6 | NSUN7 | NT5C | NT5C1A | NT5C1B | NT5C1B-RDH14 | NT5C2 | NT5C3A